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The ability to reversibly switch between invasive and non-invasive phenotype has 
been considered to be critical for the high malignancy of melanoma. Increasing evidence 
suggests that this ability is determined by the activities of microphthalmia-associated 
transcription factor (MITF) and EMT-related transcription factors (EMT-TFs). GLI1 and 
GLI2, the components of Hedgehog (HH) pathway, are associated with progression and 
invasiveness of melanoma. Although GLI2 is known to suppress MITF expression and to 
promote invasive phenotype of melanoma, the role of GLI1 remains elusive. Here I show 
that inhibition of Shh-pathway by cyclopamine or GLI1 knockdown ( Gli1 KD) decreased 
migration and invasion activity of mouse and human melanoma without affecting MITF 
levels. I observed that Gli1 KD B16F10 melanoma cells exhibited a loss of mesenchymal-
like characteristic as indicated by an increased expression of E-cadherin and a decreased 
expression of mesenchymal markers. To gain insight into the molecular mechanism, I 
analyzed several EMT-TFs that are known to regulate melanoma invasiveness. My 
analysis suggested that the expression of SNAIL1, ZEB1, and TWIST1, but not SNAIL2 
and ZEB2, are directly regulated by GLI1. Collectively my findings suggest a regulatory 
role of GLI1 on a subset of EMT-TFs to promote invasive phenotype of melanoma 
independent of MITF.  
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Melanoma incidence is increasing over past 50 years. It represents a small 
percentage of skin cancers, but is the major cause of mortality from these cancers. The 
primary source of melanoma is melanocytes (pigment cells) that underwent a mutation 
that lead to the constitutive activation of MAPK signaling pathway. Approximately 50% 
of melanomas harbor the activating BRAFV600E mutation. Current therapies for metastatic 
melanoma provides only transient response and modest disease-free survival.   
Tumor heterogeneity poses a major challenge for the effective treatment of cancer. 
Accumulating evidence indicates that the heterogeneity in melanoma can be driven 
through phenotypic plasticity. That is, the aggressiveness of melanoma appears to be due 
to the cancer cells’ ability to reversibly switch between different phenotypes with non-
invasive and invasive potentials. Microphthalmia-associated transcription factor (MITF) 
plays an essential role in determining the melanocyte lineage and has been proposed to 
act as a rheostat for the cellular heterogeneity in melanoma. In the rheostat model, low 
levels of MITF generate invasive, stem-like cells, whereas high MITF levels stimulate 
proliferation and inhibit invasion.  
Acquisition of invasive phenotype is an important step for metastasis of melanoma 
which involves downregulation of melanocyte differentiation program accompanied by 
decreased expression of E-cadherin, increase expression of mesenchymal markers, and 
enhanced invasion. This process resembles the epithelial-mesenchymal transition (EMT) 
in carcinoma.  Epithelial-to-mesenchymal transition (EMT) is a dynamic and reversible 
phenotypic switching process from polarized epithelial cells to motile mesenchymal cells; 
this process is essential for normal development and is widely thought to be a critical 
switch for tumor-cell invasiveness. EMT is driven by an interconnected signaling network 
of EMT-inducing transcription factors (EMT-TFs), including SNAIL, TWIST, and ZEB. 
Recent studies have shown that some EMT-TFs play important roles in malignant 
melanoma, but their regulation and function are different from those in epithelial cancers. 
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These studies also suggest that the EMT-TFs SNAIL2 and ZEB2 act as tumor-suppressor 
proteins by activating an MITF-dependent melanocyte differentiation program. 
Sonic hedgehog (Shh) signaling has critical roles in embryonic patterning, and 
aberrant Shh-signaling activation is implicated in various cancer types, including skin 
cancer. The Shh signal is transduced by a receptor complex composed of two proteins, 
Patched (PTCH) and Smoothened (SMO). The binding of Shh to PTCH relieves PTCH’s 
repression of SMO. The transcription factor glioma-associated oncogene homolog 1 
(GLI1) acts as a terminal, positive effector of Shh signaling, and Gli1 itself is a Shh-target 
gene. GLI1’s expression and activity are also regulated through a non-canonical Shh 
pathway, such as those involving hypoxia or transforming growth factor (TGF)-β. GLI1 
has been suggested to be involved in melanoma progression, although its precise role and 
the mechanism underlying invasion remain unclear. In this study, we show that GLI1 has 
a role in maintaining the invasive and mesenchymal-like properties of melanoma cells. 
 To examine the role of Shh signaling in maintaining the invasive phenotype of 
melanoma cells, I blocked the Shh-GLI signaling pathway using cyclopamine, an 
inhibitor of SMO. B16F10 cells were treated with cyclopamine at relatively low 
concentrations, 2.5 µM and 5 µM. The inhibition of Shh-GLI signaling pathway was 
confirm as shown by decreased levels of GLI1 protein and of GLI-mediated 
transcriptional activity, in a dose-dependent manner. GLI2 protein levels was decreased 
by cyclopamine, but to a lesser degree than GLI1. The processed, repressive form of GLI3 
(GLI3-R) was slightly increased, and full-length GLI3 (GLI3-FL) was decreased, in 
cyclopamine-treated B16F10 cells in a dose-dependent manner. Blocking Shh signaling 
with cyclopamine caused a dose-dependent decrease in invasion activity. 
The invasive phenotype of melanoma cells is often characterized by low levels of 
MITF. Therefore, I examined the expression levels of MITF in cyclopamine-treated 
B16F10 cells at 2.5 µM and 5 µM. The protein and mRNA levels of MITF were 
comparable among these cells. There were also no significant differences in the mRNA 
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levels Tyrosinase (Tyr), a MITF-target gene, in these cells. These results indicated that 
blocking the Shh signaling by cyclopamine at low concentration inhibits the invasion 
ability of B16F10 melanoma cells without affecting their MITF expression and activity. 
 I next asked whether GLI1 is important for the invasive phenotype of melanoma 
cells. I knockdown Gli1 in B16F10 cells using two Gli1-targeting lentiviral shRNAs 
(shGli1-1 and shGli1-2), and then examined the invasion ability and migration of the 
Gli1-knockdown (Gli1 KD) cells. The invasion ability of the KD cells was substantially 
reduced compared to that of control B16F10 cells expressing a Luc-targeting lentiviral 
shRNA (shLuc). The cell migration activity was also inhibited by knocking down Gli1. 
Furthermore, exogenous expression of GLI1 in B16F10 cells significantly increased the 
invasion activity. Then I analyzed the expression levels of MITF (protein and mRNA) 
and its target gene Tyr in the Gli1 KD B16F10 cells, and found that the MITF and Tyr 
levels were unchanged, as seen in the cyclopamine-treated B16F10 cells. I also observed 
similar effects on the cell migration and invasion abilities and the MITF expression and 
activity in GLI1 KD MeWo (wild-type BRAF/NRAS) and G361 (BRAFV600E) cells, 
metastatic human melanoma cell lines. Taken together, these results strongly suggested 
that GLI1 plays a crucial role in maintaining the invasive phenotype of melanoma cells, 
independently of the regulation of MITF expression and activity. 
The decreased invasion and migration after Gli1 KD prompted us to examine the 
metastatic ability of the KD cells in vivo. I performed an experimental in vivo metastasis 
assay, in which B16F10 cells expressing shLuc (control) or shGli1 were injected into the 
mouse tail vein, and lung metastasis was evaluated. There were many fewer metastatic 
nodules in the lungs of mice injected with shGli1-expressing cells than in the lungs of 
control B16F10-injected mice, indicating that Gli1 KD decreases the lung metastasis 
ability of B16F10 cells. 
Gli1 activity has been associated with EMT in various cancer. I question whether 
the decrease invasion and migration is also associated with this function in melanoma. 
5 
 
Further examination by phalloidin staining showed that stress fiber formation was 
severely inhibited in the Gli1 KD cells. Consistent with the changes in morphology and 
cytoskeletal structures, the expression levels of E-cadherin (protein and mRNA) were 
substantially increased, with the E-cadherin protein being predominantly localized to 
areas of cell-cell contact, in the Gli1 KD cells. Furthermore, the mRNA expression levels 
of mesenchymal markers, such as N-cadherin and vimentin were significantly decreased 
in the Gli1 KD cells compared to the shLuc-expressing control cells. Similar expression 
profiles of E-cadherin and mesenchymal markers were obtained using MeWo and G361 
cells, although there were no increased cell-cell adhesion in both cell lines as observed in 
B16F10. These results may indicate that GLI1 regulates a subset of EMT-TFs to prevent 
the reverse transition from a mesenchymal-like to an epithelial-like phenotype. 
To gain insight into the molecular mechanism, I investigated whether GLI1 
modulates the expression of key EMT-TFs, including SNAIL and ZEB family members. 
The mRNA levels of Snail1, Zeb1, and Twist1 were significantly decreased in the Gli1 
KD B16F10 cells compared to the control B16F10 cells, whereas no significant 
differences in the Snail2 or Zeb2 mRNA levels were observed between the Gli1 KD and 
control cells. Using the MatInspector software, I identified several putative GLI-binding 
sites within the one-kilobase (1-kb) upstream region of the transcriptional start sites of 
Snail1, Zeb1, and Twist1. I then conducted ChIP assays with an anti-GLI1 Ab in B16F10 
cells. The precipitated DNAs were analyzed by qPCR using primers specific for the 
GLI1-binding sites. The ChIP results revealed that GLI1 bound significantly to upstream 
region of Snail1, Zeb1, and Twist1. I then examined the effect of GLI1 overexpression on 
the potential promoters of Snail1, Zeb1, and Twist1 using reporter assays, and found that 
GLI1 overexpression substantially enhanced the promoter activities of the 1-kb regions. 
The activities were not significantly increased when the regions’ corresponding deletion 
derivatives were used. Collectively, these results strongly suggest that GLI1 binds 
directly to the promoters of Snail1, Zeb1, and Twist1, and regulates their expression. In 
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addition, I found a significant co-occurrence between Gli1 and Zeb1 (P = 0.002) and 
between Gli1 and Sail1 (P = 0.004) by analyzing the TCGA cutaneous melanoma dataset 
(287 samples with RNA sequencing expression data) through the cBioPortal for cancer 
genomic data using mutual exclusivity analysis. 
The expression level of MITF is thought to be the key factor in determining the 
proliferative or invasive state of melanoma according to MITF-dependent phenotype 
switching model. MITF is a key molecule that regulates heterogeneity in melanoma, and 
the MITF rheostat model has become widely accepted in melanoma biology. In the 
present study, I demonstrated for the first time that the transcription factor GLI1 plays an 
important role in maintaining the invasive phenotype of melanoma cells without affecting 
the MITF expression and activity. I also showed that GLI1 prevents the reversal of the 
mesenchymal-like phenotype of melanoma cells, most likely by modulating a subset of 
EMT-TFs. These findings provide new insight into how a high degree of heterogeneity 
and plasticity is achieved and regulated in melanoma. 
Recent studies have shown that a switch in the EMT-TF expression pattern from 
SNAIL2high/ZEB2high/TWIST1low/ZEB1low to SNAIL2low/ZEB2low/TWIST1high/ZEB1high 
occurs during melanoma progression. In this study, I found that Gli1 KD induced a 
mesenchymal-epithelial-like transition in melanoma cells, which was accompanied by 
severely decreased invasive and migratory properties, and by an increased expression of 
E-cadherin and downregulation of mesenchymal markers. I also observed decreased 
mRNA levels of Snail1, Zeb1, and Twist1, but not of Snail2 or Zeb2, in the Gli1 KD 
melanoma cells. It is reported that SNAIL1 and TWIST1 cooperatively control Zeb1 
expression during EMT in epithelial cells. Taken together with the results of my ChIP 
and Luc reporter assays, it is conceivable that GLI1 directly regulates the transcriptional 
expression of a subset of EMT-TFs, including Snail1 and Twist1, as in non-melanoma 
cancer cells, to maintain the invasive activity of melanoma cells through MITF-
independent mechanisms. Further studies are needed to clarify this issue. 
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An increased expression of Gli1 has been observed in BRAFi-resistant melanoma 
cells and patient samples, as well as during melanoma progression. Taken together with 
my present results, GLI1 may play a role in generating a high level of intratumor 
heterogeneity in melanoma. Targeting GLI1 may therefore be an effective approach for 
melanoma therapy. Indeed, accumulating evidence suggests that GLI antagonists, of 
which GANT61 has been most extensively studied in vitro and in animal models, are 
promising therapeutic candidates for a wide range of cancers, including melanoma. 

